Syros Pharmaceuticals, Inc. (LON:0LC7)

Market Cap	3.93K -99.9%
Revenue (ttm)	288.00K -95.6%
Net Income	-72.98M
EPS	-1.98
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,356
Average Volume	1,744
Open	0.0008
Previous Close	0.0008
Day's Range	0.0008 - 0.0008
52-Week Range	0.0001 - 0.2937
Beta	1.08
RSI	44.63
Earnings Date	Mar 2, 2026

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company’s lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2011
• Employees: 68
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0LC7

Financial Performance

In 2023, Syros Pharmaceuticals's revenue was $9.94 million, a decrease of -33.23% compared to the previous year's $14.88 million. Losses were -$164.57 million, 73.9% more than in 2022.

Financial numbers in USD